Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1982800 | 1.00 | CHRNB2 (0.44) | CHRNB2CHRNB4CHRNA3CHRNA4CHRM2 | |
| SCHEMBL1982802 | 1.00 | CHRNB2 (0.44) | CHRNB2CHRNB4CHRNA3CHRNA4CHRM2 | |
| SCHEMBL14196282 | 0.89 | CHRNB2 (0.47) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL30418778 | 0.89 | CHRNB2 (0.47) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL4729568 | 0.89 | CHRNB2 (0.47) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL652903 | 0.84 | NPC1 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4POLB | |
| SCHEMBL652905 | 0.84 | NPC1 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4POLB | |
| SCHEMBL652904 | 0.84 | NPC1 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4POLB | |
| SCHEMBL29264141 | 0.84 | NPC1 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4POLB | |
| SCHEMBL14222790 | 0.81 | CHRNB2 (0.49) | CHRNB2CHRNB4CHRNA3CHRNA4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1767536-B1 | QUINOLONECARBOXYLIC ACID COMPOUNDS, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | INST MED BIOTECHNOLOGY CAMS (CN) | 2011-06-29 | — | — | EP | disclosed |
| US-7759362-B2 | Quinolonecarboxylic acid compounds, preparation methods and pharmaceutical uses thereof | INSTITUT OF MEDICINAL BIOTECHNOLOGY CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2010-07-20 | — | — | US | disclosed |
| US-20070219231-A1 | Quinolonecarboxylic acid compounds, preparation methods and pharmaceutical uses thereof | XINCHANG PHARMACEUTICAL FACTORY, ZHEJIANG MEDICINE CO. LTD. (CN) | 2007-09-20 | — | — | US | disclosed |
| WO-2007070613-A2 | RIFAMYCIN ANALOGS AND USES THEREOF | ACTIVBIOTICS, INCORPORATED (US) | 2007-06-21 | — | — | WO | disclosed |
| EP-1767536-A1 | QUINOLONE CARBOXYLIC ACID DERIVATIVES, THEREOF PREPARATION AND USAGE | Institute of Medicinal Biotechnology, Chinese Acadamy of Medical Sciences (CN) | 2007-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219231-A1 | Quinolonecarboxylic acid compounds, preparation methods and pharmaceutical uses thereof | NQO2, ABCG2, DHX15 | CHRNB2 4811/4885CHRNB4 4734/4885CHRNA3 4496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.